Antibody-Based Drug Discovery At The Speed Of Light

Combining the PentaMice® platform with single B cell screening using the Berkeley Lights Beacon® Optofluidic system offers a powerful solution for accelerating the development of monoclonal antibody therapeutics. The Beacon® system leverages cutting-edge technology — including light manipulation, nanofluidics, and advanced AI algorithms — to isolate and maneuver individual B cells into NanoPen™ chambers for high-throughput screening. This integrated approach significantly enhances speed to market by streamlining early discovery and selection of candidate antibodies.

Our white paper explores key insights into this process, including First-to-Human antibody development strategies, the use of the PentaMice® platform for targeted immunization, and the precision of single B cell screening. Additional topics include sequence identification, custom bioinformatics solutions, and gene-to-protein expression strategies. A featured case study highlights the successful discovery of diverse monoclonal antibodies targeting SARS-CoV-2 Delta and Omicron spike proteins.

Download the white paper to learn how this end-to-end workflow can drive efficiency and innovation in antibody discovery.